Ke Ning Bio

The company's business model centers on leveraging its proprietary biomaterial design technology to address significant unmet medical needs. It operates with a multi-platform strategy to regulate pharmaceutical products, establishing research centers in both Shenzhen and Shanghai. The business makes money by developing and bringing to market a pipeline of pharmaceutical products. A significant milestone was achieved in April 2022, when the company secured close to 100 million RMB in a Pre-A funding round led by Lapam Investment, with participation from Kaitai Capital and existing shareholder Zero2IPO Venture. This capital is intended to support the preclinical development of its pipelines, particularly in ophthalmology and orthopedics. In 2021, Pleryon established a residency in JLABS@Shanghai, a life science incubator under Johnson & Johnson Innovation.

Pleryon's product pipeline is diverse, utilizing its technology to enable previously undruggable compounds to be developed as therapeutics. Key products in development include a contact lens lubricant, veterinary therapeutics for dry eye, and a long-acting anti-VEGF therapeutic for age-related macular degeneration. The company's programs are primarily focused on osteoarthritis, ophthalmology, and regenerative aesthetics. By employing advanced polymer and drug delivery systems, Pleryon aims to create a scalable product pipeline with substantial market potential.